"In an early clinical trial, a personalized vaccine safely stimulated the immune systems of people with a fatal type of brain tumour called glioblastoma, which has a median survival time of less than 18 months."
"The personalized treatment encourages the immune system to attack the tumours called glioblastomas."
A personalized vaccine was tested in an early clinical trial for glioblastoma, a fatal brain tumor with a median survival time of less than 18 months. The vaccine was designed to stimulate the immune system in people with this condition. Results from the trial indicate that the personalized vaccine safely activated immune responses. The immune activation is intended to drive the immune system to attack glioblastoma tumors. The approach aims to improve outcomes in a disease with very limited survival time by leveraging individualized immune stimulation.
Read at Nature
Unable to calculate read time
Collection
[
|
...
]